國家衛生研究院 NHRI:Item 3990099045/10714
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 956472      線上人數 : 874
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10714


    題名: Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
    作者: Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S
    貢獻者: National Institute of Cancer Research
    摘要: Introduction: In the global, randomized phase 3 NAPOLI-1 study, liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) significantly increased median OS vs. 5-FU/LV by 45% (6.1 vs. 4.2 mo; unstratified HR = 0.67 [0.49–0.92]; p=.012) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy. Here, we present a subgroup analysis by prior non-liposomal irinotecan (NLI). Methods: Study methodology has been published (Wang-Gillam; Lancet 2016). Robustness of overall treatment effect was assessed by prospectively-defined subgroups, including prior NLI, based on primary survival analysis data (cut-off February 2014) of the ITT population.Results: OS, PFS and CA19-9 response rates in pts with (n¼29) and without (n¼207) prior NLI are shown (see Table). In pts without prior NLI, nal-IRIþ5-FU/LV (n¼105) improved median OS vs. 5-FU/LV (n¼102) by 2.5 mo to 6.7 mo (HR¼0.62; p<.01). Most frequent TEAEs were GI disorders (diarrhea, vomiting, nausea), regardless of prior NLI. ≧Grade 3 TEAEs and TEAEs leading to dose modification were similar in pts with (9 [75%]; 6 [50%]) and without (81 [77%]; 77 [73%]) prior NLI in the nalIRIþ5-FU/LV arm. Conclusion: This post-hoc subgroup analysis shows significant increases for nalIRIþ5-FU/LV vs. 5-FU/LV in OS, PFS and CA19-9 response rates in pts without prior NLI. Outcomes were similar in both arms in pts with prior NLI. The low number ofpts with prior NLI preclude firm conclusions from being drawn and further research is needed to explore the impact ofprior NLI.
    日期: 2017-06-26
    關聯: Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018.
    Link to: http://dx.doi.org/10.1093/annonc/mdx263.017
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000405528100409
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85079494058
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000405528100409.pdf239KbAdobe PDF179檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋